Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: A cross-sectional analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Arends, Suzanne ^a,b   Spoorenberg, Anneke ^a   Efde, Monique ^b   Bos, Reinhard ^b   Leijsma, Martha K ^a   Bootsma, Hendrika ^a   Veeger, Nic J G M ^a   Brouwer, Elisabeth ^a   Van Der Veer, Eveline ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ANKYLOSIS; ARTHRITIS; ARTICLE; BONE DENSITY; BONE GROWTH; BONE TURNOVER; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GENDER; HIP; HUMAN; HUMAN CELL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MODIFIED STOKE AS SPINAL SCORE; OSSIFICATION; OSTEOLYSIS; PROTEIN BLOOD LEVEL; PSORIASIS; SCORING SYSTEM; SPINE RADIOGRAPHY; SYNDESMOPHYTE; UVEITIS; ADVERSE EFFECTS; BLOOD; BONE DEVELOPMENT; LUMBAR VERTEBRA; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION INJURY; RADIOGRAPHY;

ADULT; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RADIATION INJURIES; RADIOGRAPHY; SPONDYLITIS, ANKYLOSING;

EID: 84903391557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099685     Document Type: Article

References (37)

1. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, et al. (2007) Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66: 910-915. (Pubitemid 46999792)
2. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369: 1379-1390. (Pubitemid 46590387)
3. Baraliakos X, Listing J, von der Recke A, Braun J (2009) The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients. J Rheumatol 36: 997-1002.
4. van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, et al. (2012) Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 71: 518-523.
5. Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, et al. (2013) Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204055. [Epub ahead of print].
6. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64: 1388-1398.
7. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, et al. (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65: 2645-2654.
8. Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19: 335-339. (Pubitemid 46884187)
9. Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, et al. (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68: 1839-1842.
10. Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, et al. (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44: 772-776.
11. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, et al. (2011) The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 22: 1431-1439.
12. Lange U, Teichmann J, Strunk J, Muller-Ladner U, Schmidt KL (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16: 1999-2004. (Pubitemid 41790919)
13. El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71: 291-295.
14. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, et al. (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56: 1846-1853. (Pubitemid 47110384)
15. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, et al. (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60: 3257-3262.
16. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, et al. (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71: 572-574.
17. Park MC, Chung SJ, Park YB, Lee SK (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 49: 288-294.
18. Vosse D, Landewe R, Garnero P, van der Heijde D, van der Linden S, et al. (2008) Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 47: 1219-1222. (Pubitemid 352038230)
19. Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, et al. (2012) The effect of three years of TNFalpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14: R98.
20. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361-368. (Pubitemid 14134775)
21. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, et al. (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65: 316-320. (Pubitemid 43268219)
22. Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, et al. (2004) Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 31: 125-132. (Pubitemid 38067534)
23. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, et al. (2004) What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 50: 2622-2632. (Pubitemid 39062724)
24. The International Society for Clinical Densitometry. Available at: http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/. Accessed 2014 January 15.
25. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, et al. (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21: 2286-2291.
26. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, et al. (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68: 18-24.
27. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, et al. (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68: 1811-1818.
28. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, et al. (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21: 2281-2285.
29. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
30. Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, et al. (2007) Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 66: 633-638. (Pubitemid 46707132)
31. Boonen A, vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, et al. (2009) Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 36: 1249-1255.
32. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, et al. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22: 391-420.
33. Acebes C, de la Piedra C, Traba ML, Seibel MJ, Garcia Martin C, et al. (1999) Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. Clin Chim Acta 289: 99-110. (Pubitemid 29505203)
34. Mitra D, Elvins DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 26: 2201-2204. (Pubitemid 29487017)
35. Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, et al. (2009) Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 36: 1785-1791.
36. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32: 1290-1298. (Pubitemid 40995385)
37. Machado P, Landewe R, Lie E, Kvien TK, Braun J, et al. (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70: 47-53.